Recently presented data from the ALITHIOS open-label extension (NCT03650114) showed that ofatumumab (Kesimpta; Novartis), an FDA-approved disease-modifying therapy for relapsing multiple sclerosis (MS), is effective in reducing serum neurofilament light (sNfL) and improving no evidence of disease activity (NEDA) rates among various racial and ethnic subgroups.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045